TSZY(SZ:002872) Shang Hai Zheng Quan Bao·2025-08-11 18:53Core Viewpoint - Tian Sheng Pharmaceutical Group Co., Ltd. is under risk warning due to the alleged misappropriation of company funds by its controlling shareholder, Liu Qun, which has led to the implementation of risk warnings on its stock trading since June 5, 2019 [2][3]. Group 1: Risk Warning Implementation - The stock trading of Tian Sheng Pharmaceutical has been subject to risk warnings since June 5, 2019, due to allegations against controlling shareholder Liu Qun for misappropriating company funds [2][3]. - Liu Qun's assets related to the case have been seized, frozen, or sealed, making it unlikely for the funds to be returned within a month [3]. Group 2: Measures Taken and Progress - The company has enhanced training for its board members and management on relevant laws and regulations to improve compliance awareness and ensure effective implementation of internal controls [4]. - As of April 8, 2021, Liu Qun has fully repaid the misappropriated funds, totaling RMB 125,074,926, including interest [5][8]. - The company has engaged Beijing Xinghua Accounting Firm to audit the repayment situation, which confirmed that all funds have been repaid, although uncertainties remain regarding the completeness and accuracy of the repayment [5][6]. Group 3: Legal Proceedings and Outcomes - On December 29, 2023, the Chongqing First Intermediate People's Court issued a judgment ordering Liu Qun to repay RMB 9,182.4926 million and RMB 3,325 million, both of which have been returned [7]. - Liu Qun appealed the judgment, but on August 8, 2024, the Chongqing High People's Court upheld the original ruling, confirming the total misappropriated amount [8]. - The company is currently under investigation by the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure laws [9].